In melanoma, low ESRP1 expression was correlated with greater tumor-associated immune cytolytic activity and patients with low ESRP1 expression showed a favorable survival, suggesting the potential utility of ESRP1 as a biomarker in predicting response to immunotherapy [22]. The gene discussed is ESRP1; the disease is melanoma.